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Bureaucrats vs. Physicians: Have Doctors Been 
Stripped of Their Power to Determine the Proper  
Use of Human Growth Hormone in Treating  
Adult Disease? 
Ryan Cronin∗ 
INTRODUCTION 
It recently has been suggested that millions of dollars in human 
growth hormone (hGH) prescriptions are being distributed illegally. 
Articles appearing in non-legal publications have made claims that 
hGH may not be prescribed off-label. Further, these articles have 
presented legal analysis laying out narrow legal parameters within 
which hGH may be prescribed. In opinion letters, the Food and Drug 
Administration (FDA) has agreed with this interpretation of hGH 
regulation. Proponents of hGH in the anti-aging community have 
responded by challenging the validity of this interpretation. This 
controversy has left doctors unsure of which hGH treatments are 
legal. 
In an article appearing in the Journal of the American Medical 
Association (JAMA), the authors purported to address the legalities 
of prescribing hGH.1 The article suggested that two specific 
diagnostic criteria must be met to legally diagnose growth hormone 
deficiency (GHd) before hGH may be legally prescribed as a 
 
 ∗ J.D. (2008), Washington University School of Law; B.A. (2002), Loyola College in 
Maryland. Special thanks to my parents, Edward and Mary Cronin, as well as Thomas and 
Mary Greene, Todd Richheimer, and Thomas Garry, Esq. Additional thanks to the staff of the 
Washington University Journal of Law & Policy. 
 1. Thomas T. Perls, Neil Reisman & S. Jay Olshansky, Provision or Distribution of 
Growth Hormone for “Antiaging”: Clinical and Legal Issues, 294 JAMA, 2086, 2087 (2005). 
See also Thomas T. Perls, Anti-Aging Quackery: Human Growth Hormone and Tricks of the 
Trade—More Dangerous than Ever, 59A J. GERONTOLOGY: BIOLOGICAL SCI. 682 (2004).  
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treatment.2 However, there is little support in the law to support a 
requirement for doctors to conduct these tests before diagnosing 
GHd. Accordingly, the authors only use an obscure letter written by a 
regulatory review officer at the Department of Health and Human 
Services as legal support.3  
The JAMA article, along with a later article appearing in 
Brandweek,4 prompted a response from the anti-aging community. 
Attorney Rick Collins, in a lecture to the 13th Annual International 
Congress on Anti-Aging Medicine, criticized Dr.Perls’ legal analysis 
in the JAMA article.5 Mr. Collins addressed the legislative intent 
behind the provisions of the Food, Drug and Cosmetic Act (FDCA) 
 
 2.  Perls, supra note 1, at 2087. These two criteria are: (1) biochemical diagnosis by 
means of a subnormal response to the standard growth hormone stimulation test (peak GH, < 
5.0 ng/L), and (2) patient must be growth hormone deficiency as a result of pituitary disease, 
hypothalamic disease, surgery, radiation therapy, or trauma or patients who were GH deficient 
during childhood. Id. 
 3. Letter from Debi Tran, Regulatory Review Officer, Division of Drug Marketing, 
Advertising, and Communications, Department of Health and Human Services to Robert L. 
Garnick, Ph.D., Senior Vice President, Regulatory Affairs, Quality & Corporate Compliance 
(Aug. 25, 2003) (on file with author). This letter objected to Genetech, Inc.’s dissemination of 
promotional materials related to certain hGH products. Id. The objection was that the company 
failed to provide risk information in its advertising materials. Id. The letter also indicated that 
approved hGH products (specifically Nutropin and Nutropin AQ) are only approved for use in 
adults who meet the two on-label diagnostic criteria. Id. 
 4. Jim Edwards, Bad Medicine, Brandweek, Mar. 20, 2006, available at http:// 
www.brandweek.com/bw/search/article_display.jsp?vnu_content_id=1002199181. This article 
examined the situation where Pharmecia (now owned by Pfizer) allegedly sold and marketed 
hGH products for anti-aging purposes. Id. The issue in that case was whether “Pharmecia and 
its marketing department [was] in knowing violation of an established [albeit confusing] law, or 
were they merely pigeons, bagged by a genuine ignorance of regulations and internal 
communication failures within the company?” Id. Most notably, the article stated that the 
FDCA  
explicitly bans anyone from promoting or selling growth hormone for off-label uses. 
Under the law, Genotropin was legally approved only for a narrow range of genetic 
disorders, most commonly for children with stunted bodies that refuse to grow 
normally. That market is lucrative-treating one child can cost as much as $35,000 a 
year- but also extremely limited; in the U.S., perhaps 150,000 children need growth 
hormone treatment at any one time.  
Id. 
 5. Rick Collins, Attorney, Collins, McDonald: Gann, P.C., Address at the 13th Annual 
International Congress on Anti-Aging Medicine: The Legal Front: What’s New with hGH and 
Testosterone Replacement Therapy (Oct. 26, 2005). See http://www.cmgesq.com; see also 
http://www.rickcollinsonline.com. Rick Collins is an authority on nutritional supplement law 
and sports drug defense. He represents such other groups as the International Society of Sports 
Nutrition and the International Federation of Body Builders. Id.  
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that restricts hGH.6 He specifically stated that “any implication that 
the statute was intended to prohibit hormone replacement in mature, 
clinically deficient adults is incorrect.”7 He went on to state that 
while the use of hGH for non-medical reasons is illegal, nothing in 
the statute “explicitly states anything about methods of diagnosis.”8  
Although it is possible that physicians are using less precise tests 
to diagnose GHd in adults who show symptoms associated with age-
related decline,9 there is no statutory language that explicitly restricts 
physicians from diagnosing GHd as they see fit. Dr. Pearl’s analysis 
would result in the prescription of hGH being more heavily regulated 
than actual controlled substances such as anabolic steroids or 
Oxycontin, both with a recognized potential for abuse.10 It would be 
up to Congress to place higher restrictions on hGH if it felt it 
necessary. Based on the legislative history behind the current laws, 
Congress has indicated no such intention.11 
Part I of this Note examines the legislative history behind the 
FDCA and explains off-label prescription practices. It will also 
present studies indicating the benefits and possible negative side 
effects of hGH. Part II analyzes the legislative intent behind adding 
hGH to the FDCA in 1990, the appropriate deference to be given to 
the FDA’s interpretation of the statute, and the policy considerations 
 
 6. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301–395 (2005).  
(W)hoever knowingly distributes, or possesses with intent to distribute, human growth 
hormone for any use in humans other than the treatment of a disease or other 
recognized medical condition, where such use has been authorized by the Secretary of 
Health and Human Services under 505 [21 U.S.C. § 355] and pursuant to the order of a 
physician, is guilty of an offense punishable by not more than 5 years in prison, such 
fines as are authorized by title 18, United States Code, or both. 
21 USC § 333(e)(1) (2000). 
 7. Collins, supra note 5. 
 8. Id. “The natural aging process is neither a disease nor other recognized medical 
condition, “anti-aging therapy” is not a valid use for hGH.” Id. He further noted that 
performance enhancement is not a valid use. Id. 
 9. Perls, supra note 1, at 2088. The author suggests that doctors are diagnosing growth 
hormone deficiency in adults by testing IGF-1 levels (a proxy for GH levels) in older adults. Id. 
Perls states that this is not a scientific or legally accepted diagnosis of the disease. Id. 
 10. 21 U.S.C. § 812 (2000). Anabolic steroids are Schedule III drugs which have potential 
for abuse and dependence, but also have accepted medical uses. Id.  
 11. See generally S. 1829, S. REP. NO. 101-433.  
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surrounding the regulatory scheme for hGH. Part III will suggest 
guidance to doctors who prescribe hGH under the current laws. 
I. THE CONTROVERSY SURROUNDING THE OFF-LABEL PRESCRIPTION 
OF HGH TO ADULTS 
A. Why hGH Has Become Popular Among “Anti-Aging” Medical 
Practitioners 
The FDA approved hGH as a new drug in 1940.12 In 1990, a study 
reported the beneficial effects on body composition of administering 
hGH to twelve elderly men.13 Two recent studies confirmed these 
findings.14 The original study was influential in the creation of the 
anti-aging industry.15 
Although hGH was once expensive and difficult to obtain, 
scientific advances have made the hGH supply virtually unlimited.16 
Now, the distribution of hGH has grown into a multimillion-dollar 
anti-aging industry.17 It has been estimated that as much as 30% of 
 
 12. Letter from Michael A. Chappell, Dist. Director, Dallas District Office, Dep’t of 
Health and Human Servs., to Tony Stires, Global Internet Alliance (Feb. 18, 2004) (on file with 
author). Prior to its approval as a new drug in 1940, growth hormone was neither marketed as a 
dietary supplement, nor as a food. Id. “Therefore, growth hormone is excluded from the 
definition of a dietary supplement.” Id.  
 13. Mary Lee Vance, Can Growth Hormone Prevent Aging?, 349 NEW ENG. J. MED., 779, 
779 (2003) (citing D. Rudman et al., Effects of Human Growth Hormone in Men Over 60 Years 
Old, 323 NEW ENG. J. MED. 1, 1–6 (1990)). Twelve men between the ages of 61 and 81 who 
had IGF-1 levels lower than those found in normal young men took growth hormone for six 
months. Id. This test showed an increase in lean body mass, decrease in adipose mass, and an 
increase in lumbar spine density. Id.  
 14. Vance, supra note 13, at 779 citing (MR Blackman et al., Growth Hormone and Sex 
Steroid Administration in Healthy Aged Women and Men: A Randomized Controlled Trial, 288 
JAMA 2282–92 (2002); MA Papadakis et al., Growth Hormone Replacement in Older Men 
Improves Body Composition But Not Functional Ability, 124 ANN. INTERN. MED. 708–16 
(1996)).  
 15. Vance, supra note 13, at 779.  
 16. Jeffrey Hedges, The Anabolic Steroids Act: Bad Medicine for the Elderly, 5 ELDER. 
L.J. 293, 300–01 (1997). “Originally hGH was difficult and expensive to obtain because it had 
to be extracted from the pituitary glands of cadavers. With the advent of synthetic replication, 
the supply of hGH is no longer limited.” Id. 
 17. Perls, supra note 1, at 2086. “Worldwide annual sales of GH are estimated to be $1.5 
to $2 billion.” Id. It has been suggested that 30% of these prescriptions in the United States are 
for off-label uses. Id. It has further been estimated that “212,921 new and refill GH 
prescriptions were filled by retail and mail service pharmacies in 2004. . . . These prescriptions 
https://openscholarship.wustl.edu/law_journal_law_policy/vol27/iss1/9
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the hGH prescriptions in the United States are for uses not approved 
by the FDA.18 In 2004 alone, the United States government estimated 
that between 25,000 and 30,000 older individuals were treated with 
hGH for anti-aging.19 
B. History of Off-Label Prescriptions 
When a manufacturer applies for approval of a new prescription 
drug, the manufacturer must submit proposed labeling to the FDA.20 
This labeling, if approved, becomes the package insert that 
accompanies the drug itself when it is prescribed.21 Drugs prescribed 
for applications not on the insert, and therefore, approved by the 
FDA, are referred to as “off-label.”22 Once a drug is approved for one 
purpose, physicians are free to prescribe it off-label.23 Estimates vary, 
but at least half of all prescriptions in the United States are off-
label.24 
Physicians are free to prescribe drugs for both on- and off-label 
uses.25 Many off-label uses are widely known and often widely 
 
generated total sales of $622 million. . . . of these GH prescriptions, 74% were for individuals 
aged 20 years and older and 43.7% were for individuals aged 40 to 59 years.” Id. It is worth 
noting that in 2002 an estimated 100,000 others obtained hGH without a prescription. Id. See 
also Vance, supra note 13.  
 18. Perls, supra note 1. A larger problem exists in the distribution and marketing of hGH 
over the internet. Id. Many web sites boast the anti-aging benefits of hGH and misrepresent the 
potential side effects. Id. Further, in many cases hGH has been distributed over the internet 
without the required physician supervision. Id.  
 19. Id. 
 20. Kaspar J. Stoffelmayr, Products Liability and “Off-Label” Uses of Prescription 
Drugs, 63 U. CHI. L. REV. 275, 276 (1996). 
 21. Id. 
 22. Id. 
 23. Maxwell J. Mehlman, Elizabeth Banger & Matthew M. Wright, Health Law 
Symposium: Doping in Sports and the Use of State Power, 50 ST. LOUIS L.J. 15, 56 (2005).  
 24. Id. See also Steven R. Salbu, Off-Label Use, Prescription, and Marketing of FDA-
Approved Drugs: An Assessment of Legislative and Regulatory Policy, 51 FLA. L. REV. 181 
(1999); see also Stoffelmayr, supra note 20. 
 25. 59 Fed. Reg. 59, 820, 59, 821 (Nov. 18, 1994). “Once a [drug] product has been 
approved for marketing, a physician may prescribe it for uses or in treatment regimens of 
patient populations that are not included in approved labeling.” Id. The publication further 
stated “‘unapproved’ or, more precisely, ‘unlabeled’ uses may be appropriate and rational in 
certain circumstances, and may, in fact reflect approaches to drug therapy that have been 
extensively reported in medical literature . . . . Valid new uses for drugs already on the market 
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recommended within the medical profession.26 Manufacturers, due to 
the extreme time and financial cost of FDA approval, do not always 
seek approval for these “off-label” uses.27 Further, a company’s 
patent will often run out before it can receive the financial gain 
necessary for the investment.28 As a result, there is often no incentive 
for companies to seek FDA approval for every off-label use of their 
drugs.29 The result is that an off-label drug might still be the best and 
most reliable treatment for a patient.30  
C. The Controlled Substances Act 
In addition to prescription drugs being regulated by the FDA, 
some drugs are also regulated under the Controlled Substances Act 
(CSA).31 FDA approved drugs simultaneously regulated under the 
 
are often first discovered through serendipitous observations and therapeutic innovations, 
subsequently confirmed by well-planned and executed clinical investigations.” Id. 
 26. Stoffelmayr, supra note 20, at 277. 
 27. Id. 
 28. Id. “If an off-label use is already well known among physicians, adding it to the label 
would likely have little effect on sales. Additionally, since less than the full life of a drug’s 
patent usually remains when off-label uses become known, it is harder for a drug manufacturer 
to recover its investment in having an off-label use approved than it is to recover the initial 
investment in having the drug approved for it original use.” Id. 
 29. Id. 
 30. Id. at 278. An officer of the American Medical Association has stated that “in some 
cases, if you didn’t use the drug in the off-label way, you’d be guilty of malpractice.” Id. See 
also James O’Reilly & Amy Dalal, Off-Label or Out of Bounds? Prescriber and Marketer 
Liability for Unapproved Uses of FDA-Approved Drugs, 12 ANNALS HEALTH L. 295, 298 
(2003). This is particularly true in the case of rare disease. Id. Off-label prescriptions make up 
80–90% of drugs used to treat rare disease. Id. Financially, it would not make sense for 
manufactures to invest in seeking FDA approval for a treatment that is rarely used. Id. 
However, in the absence of off-label applications, patients with rare diseases could be left 
without treatment options. Id.  
 31. Controlled Substances Act, 21 U.S.C. §§ 801–971 (2000). See also Congressional 
Research Service, Gonzales v. Oregon: Physician-Assisted Suicide and the Controlled 
Substances Act (Oct. 18, 2005).  
Congress enacted the CSA as Title II of the Comprehensive Drug Abuse Prevention 
and Control Act of 1970. The purpose of the CSA is to regulate the use of controlled 
substances for legitimate medical purposes and to prevent these substances from being 
diverted for illegal manufacture, distribution and use. Controlled substances are 
categorized into five schedules, ranging from Schedule I substances that have no 
currently accepted medical use in treatment and can be used in very limited 
circumstances, to substances in Schedules II, III, IV, and V that have recognized 
https://openscholarship.wustl.edu/law_journal_law_policy/vol27/iss1/9
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CSA are classified as schedule II, III, IV, and V drugs.32 In 1990, 
Congress classified anabolic steroids as a schedule III drug.33 As with 
all schedule III drugs, physicians can only prescribe steroids for 
treatment of a disease or other recognized medical condition.34  
In 1990, Congress placed anabolic steroids under the Controlled 
Substances Act.35 This was done in response to the growing problem 
of the use of anabolic steroids for performance enhancement by 
athletes.36 In the two Senate hearings leading up to the bill’s passage; 
athletes, coaches, administrators, sports medicine experts, and 
doctors testified to the widespread use of steroids in sports and to the 
resulting side effects.37 The purpose of this legislation was to “further 
restrict the use of steroids,” thus increasing penalties for steroid 
trafficking to match penalties for selling cocaine and other dangerous 
drugs.38 In the same legislation, Congress placed hGH under the 
 
medical uses and may be manufactured, distributed and used in accordance with the 
CSA. 
Id. 
 32. 21 U.S.C. § 812(b). Schedule I drugs such as marijuana are deemed to have no 
medical uses. Id. 
 33. 21 U.S.C. § 812 (2000). The criteria for classification as a Schedule III drug: 
(A) The Drug or other substance has a potential for abuse less than the drugs or other 
substances in schedules I and II. (B) The drug or other substance has a currently 
accepted medical use in treatment in the United States. (C) Abuse of the drug or other 
substance may lead to moderate or low physical dependence or high psychological 
dependence. 
21 U.S.C. § 812(b)(3). 
 34. 21 U.S.C. § 333 (2002). 
 35. Anabolic Steroid Control Act of 1990, 21 U.S.C. § 812 (2000). 
 36. S. 1829, S. REP. NO. 101-433, at 2–4 (1989). “The committee held 2 full days of 
hearings on the problem of steroid abuse, focusing on the problem of steroid abuse in amateur 
and professional sports.” Id. “Steroid abuse has become a major drug abuse problem in 
America. As many as 1 million Americans or more have used or are currently using steroids for 
non-medical purposes, primarily to increase athletic performance and improve physical 
appearance.” Id. See also Jeffrey A. Black, The Anabolic Steroids Control Act of 1990: A Need 
for Change, 97 DICK. L. REV. 131, 138 (1992) (stating “In response to the public’s growing 
concern over the use of anabolic-androgenic steroids for nonmedical purposes, Congress 
enacted the Anabolic Steroids Control Act of 1990.”). Id.  
 37. Report 1, supra note 36. 
 38. Id. at 1.  
The bill would crack down on illegal steroid use in four ways: (1) it would increase 
steroid trafficking penalties to match the penalties for selling cocaine and other 
dangerous drugs; (2) it would impose tight record-keeping and production control 
regulations to prevent the diversion of legally produced steroids into the illicit market; 
Washington University Open Scholarship
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Food, Drug and Cosmetic Act, the act which formerly regulated 
anabolic steroids.39 
D. Federal hGH Regulation 
Originally written to regulate anabolic steroids, the Food, Drug 
and Cosmetic Act (FDCA) now regulates hGH.40 As part of the 1990 
legislation increasing steroid regulation, Congress moved hGH onto 
the FDCA, filling the void left when anabolic steroids were moved 
from the FDCA to the CSA.41 The CSA expressly exempts hGH from 
its reach.42  
There was widespread concern in the medical community that 
hGH would not be treated differently than anabolic steroids.43 Dr. 
Louis Underwood, speaking on behalf of the pediatric Endocrine 
 
(3) it would give the Drug Enforcement Administration the authority and responsibility 
to investigate violations involving the illegal production, distribution, or possession 
with intent to distribute steroids; and (4) the bill would require U.S. demand reduction 
agencies to incorporate steroids in all federally supported drug abuse prevention, 
education, and treatment programs. 
Id. 
 39. Supra note 35, at sec. 1904. “This legislation would also amend the Food, Drug, and 
Cosmetic Act to restrict the illegal distribution of human growth hormone which is chemically 
distinct from steroids.” Id. See also Collins, supra note 5.  
 40. Supra note 39. 
 41. Id. 
 42. Id. at 13. “Section 101(b) creates a new subsection (41) of section 102 of the 
Controlled Substances Act (21 U.S.C. § 802), which provides a new definition for “anabolic 
steroids.” Id.  
To be classified as an anabolic steroid, and [sic] drug must be both chemically and 
pharmacologically related to the male hormone testosterone, and the drug must 
promote or purport to purport muscle growth. Section 101(b) contains a list of 27 
chemicals that are to be considered anabolic steroids under the Controlled Substances 
Act. The list, however, is not exclusive. Any drug that meets the general definition is 
[sic] paragraph (A) of the new subsection (41), except human growth hormone and 
subject to the exemptions specified in section 102 of the bill, shall be considered an 
anabolic steroid. 
Id. 
 43.  Abuse of Steroids in Amateur and Professional Athletics: Hearing Before the 
Subcomm. on Crime, of the H. Comm. on the Judiciary, 101th Cong. 81 (1990) (statement of 
Louis E. Underwood, M.D., Professor of Pediatrics, University of North Carolina at Chapel 
Hill).  
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Society of North America,44 opined that hGH should not be “tarred 
by the same brush used for anabolic steroids.”45 Dr. Underwood 
stressed the differences between anabolic steroids and hGH stating, in 
part, that the side effects of hGH are much less, hGH has not been 
shown as an effective performance enhancer, and it is produced in the 
same form in the body whereas anabolic steroids are not.46 Dr. 
Underwood believed that placing hGH under the CSA would have 
adverse effects on research being done into other uses of hGH.47 As a 
result of these concerns, Congress treated hGH differently by placing 
 
 44. Id. The Lawson Wilkins Pediatric Endocrine Society has “approximately 600 
physicians who care for children with endocrine diseases and disorders of growth. . . . this 
group prescribes most of the growth hormone used in the United States.” Id. 
 45. Id. Dr. Underwood expressed concern that the scheduling of hGH with anabolic 
steroids could have a severe impact on patients and “investigative” efforts into the beneficial 
uses of hGH. Id.  
 46. Id. at 82.  
With the exception of testosterone, the anabolic steroids are each different from 
substances produced by the body. In this sense they should be considered to be drugs. 
On the other hand, the growth hormones that we use therapeutically in short children 
are either identical to or virtually identical to the normal growth hormone made by the 
body. Anabolic steroids promote increase in muscle mass and aggressiveness. They 
can also cause sterility and a variety of different side effects that you have heard about 
here today. Growth hormone, on the other hand, has very few undesirable side effects, 
and in the 25 years we have used it in the treatment of short children, it has had 
amazingly few adverse effects. Unlike steroids, overtreatment with growth hormone 
has never been reported. I would like to emphasize that. I know of no instance in 
which it has been shown that therapeutic use of growth hormone has resulted in an 
overtreatment phenomenon. . . . 
Growth hormone doesn’t cause aggressive behavior, as we see with anabolic steroids. 
It doesn’t cause the psychological dependency that I believe we will hear about 
shortly. Growth hormone has entirely different mechanisms of metabolism than 
anabolic steroids, thereby not allowing it to build up in the body as in the case of 
anabolic steroids.  
Id. 
 47. Id. Dr. Underwood specified four specific possible adverse effects of the failure to 
uncouple growth hormone from anabolic steroids. Id. First is the “adverse psychological effect 
on the small children that receive growth hormone to grow.” Id. Children who take hGH would 
feel badly and be teased for taking a controlled substance. Second is the concern that 
“scheduling growth hormone along with steroids will create inconvenience for most patients.” 
Id. Third is the concern that there will be a “likely disruption in supply to patients who receive 
free growth hormone from the manufacturer.” Id. Increased restrictions would likely discourage 
pediatric endocrinologists from participating in the free growth hormone program. Id. And 
lastly, Dr. Underwood addressed the concern that making hGH a controlled substance would 
likely place quotas on production, leaving unavailable the free, residual hGH relied on by 
researchers. Id. 
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it under the less restrictive statute formerly regulating anabolic 
steroids, as opposed to scheduling hGH under the more restrictive 
CSA.48 The following is resulting provision of the FDCA:  
Whoever knowingly distributes, or possesses with intent to 
distribute, human growth hormone for any use in humans other 
than the treatment of a disease or other recognized medical 
condition, where such use has been authorized by the Secretary 
of Health and Human Services under Section 355 of this title 
and pursuant to the order of a physician, is guilty of an offense 
punishable by not more than 5 years in prison, such fines as are 
authorized by title 18, or both.49  
This language was added at the end of congressional deliberations 
over the Crime Control Act of 1990, leaving no legislative history to 
indicate exactly what Congress intended.50  
The FDCA placed authority for its enforcement on the Drug 
Enforcement Agency (DEA).51 The FDCA authorizes the DEA to 
investigate misuse of hGH.52 Further, the Department of Justice has 
found that in order to prosecute a physician under the FDCA for 
illegal distribution of hGH, the evidence must include proof that the 
physician is a drug dealer.53 
 
 48. 21 U.S.C. § 812. 
 49. 21 U.S.C. § 333(e). 
 50. Maxwell J. Mehlman, Elizabeth Banger, & Matthew M. Wright, Health Law 
Symposium: Doping in Sports and the Use of State Power, 50 ST. LOUIS. U. L.J. 15, 56 (2005).  
 51.  21 U.S.C. § 333(e). “The Drug Enforcement Administration is authorized to 
investigate offenses punishable by this subsection.” Id. 
 52. Id. 
 53. U.S. DEP’T OF JUSTICE, CIVIL RESOURCE MANUAL 19, HUMAN GROWTH HORMONE/ 
STEROIDS STATUTORY OVERVIEW (1998).  
Prosecuting a physician brings other considerations into play. Because section 
333(f)(1) allows physicians to distribute human growth hormone in connection with 
either (1) treatment of a disease or (2) other recognized medical condition[s] which 
[have] been authorized by the Secretary of Health and human Services, additional 
evidence is necessary to prove that a physician is a drug dealer. Obtaining such 
evidence can be difficult. Consideration should be given to attempting “controlled 
buys” using undercover agents or informants. Both search warrants and grand jury 
subpoenas for the physician’s medical files will often need to be utilized. Of course, in 
so doing, care must be given to protect the bona fide privacy interests of any legitimate 
patients the physician might.  
Id. 
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E. hGH Approved for Use in Adults 
In 1996, the FDA approved a new condition, adult GHd, for 
which hGH could be prescribed.54 This signified the first time that 
hGH could legally be given to adults.55 This created confusion as to 
what the FDA now permitted, and confused the application of the 
1990 law which is still in effect.56 However, the FDA has taken a 
strict view of the law’s application and asserts that a physician who 
prescribes hGH for an unauthorized use violates federal law.57 
Based on its interpretation of the statute, the FDA would read the 
statutory language to imply that physicians cannot prescribe hGH off-
label.58 However, if this interpretation is applied it would “constitute 
an unprecedented intrusion into physicians’ prescribing authority.”59 
“This language was added at the end of congressional deliberations 
over the Crime Control Act of 1990 and there is absolutely no 
legislative history to explain what Congress intended.”60 
According to the Department of Justice, the FDCA is read as 
allowing physicians to “distribute human growth hormone in 
connection with either (1) treatment of a disease or (2) other 
recognized medical condition which has been authorized by the 
Secretary of Health and Human Services . . . .”61 The Department of 
 
 54. FDA Drug Approvals for August 1996, http://www.fda.gov/ cder/da/da896.htm (on 
August 1, 1996, the FDA approved an application from Eli Lilly and Co. for Humatrope, the 
first product of human growth hormone approved to treat growth hormone deficiency in adults.) 
See also Edwards, supra note 4. “A classic case of AGHD would be a growth-deficient child 
entering adulthood or a cancer patient whose glands have been crippled by radiation therapy.” 
Id. 
 55. Edwards, supra note 4.  
In 1996 . . . the FDA changed the rules slightly, by approving a new diagnosis under 
which growth hormone could be administered: adult growth hormone deficiency. A 
classic case of AGHD would be a growth-deficient child entering adulthood or a 
cancer patient whose glands have been crippled by radiation therapy. The new 
approval still did not cover anti-aging, but an important door had been opened: For the 
first time growth hormone could be legally given to adults.  
Id.  
 56. Id. 
 57. Id. See also Perls et al., supra note 1; see also Collins, supra note 5. 
 58. Mehlman et al., supra note 50.  
 59. Id.  
 60. Id. 
 61. UNITED STATES DEPARTMENT OF JUSTICE, CIVIL RESOURCE MANUAL 19, HUMAN 
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Justice apparently believes, as evidenced by its disjunctive 
interpretation of “or” in the statute, that the “treatment of a disease” 
does not have to be approved by the Secretary of Health and Human 
Services.62 Under this interpretation, the restriction would only apply 
to “other recognized medical conditions.”63  
F. Gonzales v. Oregon and Administrative Deference 
As recently as 2006, the Supreme Court has prevented the federal 
government, specifically the Attorney General, from making medical 
policy decisions absent Congressional intent.64 In Gonzales, a patient 
was prescribed a drug which fell under the CSA.65 This drug was 
prescribed as a means for carrying out physician-assisted suicide, 
legal in the state of Oregon.66 The court examined the legislative 
history behind the CSA and determined that Congress intended the 
CSA to prevent drug abuse by requiring a physician’s prescription for 
Schedule II drugs.67 Nothing in that act prevented doctors from 
prescribing drugs for medical practices which are legal.68 
 
GROWTH HORMONE/ STEROIDS STATUTORY OVERVIEW (1998) (emphasis added).  
 62. Id.  
 63. Id. 
 64. Gonzales v. Oregon, 546 U.S. 243 (2006).  
 65. Id. at 243. The State of Oregon along with other plaintiffs brought an action seeking 
relief that would prevent the federal enforcement of the United States Attorney General’s 
interpretive rule which would have physicians who assist patients with suicide pursuant to the 
Oregon Death With Dignity Act (ODWDA) would be violating the CSA. Id. at 243–44. 
 66. Id. at 243.  
In 1994, Oregon became the first State to legalize assisted suicide when voters 
approved a ballot measure enacting the Oregon Death With Dignity Act 
(ODWDA). . . . ODWA exempts from civil or criminal liability state-licensed 
physicians who, in compliance with the specific safeguards in ODWA, dispense or 
prescribe a lethal dose of drugs upon the request of a terminally ill patient. . . . 
The drugs Oregon physicians prescribe under ODWDA are regulated under a federal 
statute, the Controlled Substances Act (CSA). . . . The CSA allows these particular 
drugs to be available only by a written prescription from a registered physician. . . . 
Id. A November 9, 2001 Interpretive Rule issued by the Attorney General addresses the 
implementation and enforcement of the CSA with respect to ODWDA. It determines that using 
controlled substances to assist suicide is not a legitimate medical practice and that dispensing or 
prescribing them for the purpose is unlawful under the CSA. Id. at 249. 
 67. Controlled Substances Act, 21 U.S.C. §§ 801–971.  
 68. 21 U.S.C. § 801a (2000). 
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The Court in Gonzales also noted the deference to be given to an 
administrative interpretation of an ambiguous statute.69 The agency is 
given “substantial deference . . . when it appears that Congress 
delegated authority to the agency generally to make rules carrying the 
force of law, and the agency interpretation claiming deference was 
promulgated in the exercise of that authority.”70 The Court further 
noted that when an agency interpretation does not meet the 
requirements for substantial deference it is only “entitled to respect 
. . . to the extent that it has the power to persuade.”71  
In an earlier decision, the Supreme Court specifically addressed 
the level of deference to be given to an opinion letter written by an 
administrative agency.72 The Court stated that “interpretations 
 
 69. Gonzales, 546 U.S. at 247. 
 70. Id. See also Chevron U.S.A. Inc. v. Natural Res. Def. Council, 467 U.S. 837, 842–45. 
In Chevron, the Court addressed the level of deference to be given to the EPA’s definition of 
“source” under the Clean Air Act. Id. at 840. The Court upheld the EPA’s interpretation and 
developed a two-part analysis: First it must be determined whether a statute permits or forbids 
an agency’s interpretation, and second, if a statute is not clear on step one, the court decides 
whether the agency’s interpretation of a statute is reasonable or permissible. Id. If an agency’s 
interpretation is reasonable, then the court will defer to the agency’s reading of the statute. Id.  
 71. Id. See also Skidmore v. Swift & Co., 323 U.S. 134, 140 (1944): 
There is no statutory provision as to what, if any, deference courts should pay to the 
Administrator’s conclusions. And, while we have given them notice, we have had no 
occasion to try to prescribe their influence. The rulings of this Administrator are not 
reached as a result of hearing adversary proceedings in which he finds facts from 
evidence and reaches conclusions of law from findings of fact. They are not, of course, 
conclusive, even in the cases with which they directly deal, much less in those to 
which they apply only by analogy. They do not constitute an interpretation of the Act 
or a standard for judging factual situations which binds a district court’s processes, as 
an authoritative pronouncement of a higher court might do. But the Administrator’s 
policies are made in pursuance of official duty, based upon more specialized 
experience and broader investigations and information than is likely to come to a judge 
in a particular case. They do determine the policy which will guide applications for 
enforcement *140 by injunction on behalf of the Government. Good administration of 
the Act and good judicial administration alike require that the standards of public 
enforcement and those for determining private rights shall be at variance only where 
justified by very good reasons. The fact that the Administrator’s policies and standards 
are not reached by trial in adversary form does not mean that they are not entitled to 
respect. This Court has long given considerable and in some cases decisive weight to 
Treasury Decisions and to interpretative regulations of the Treasury and of other 
bodies that were not of adversary origin.  
Id.  
 72. Christensen v. Harris County, 529 U.S. 576, 587 (2000). The Court in Christensen 
determined the proper level of deference to be given to an opinion letter written by the 
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contained in . . . opinion letters are entitled to respect under [its] 
decision in Skidmore v. Swift and Co. but only to the extent that those 
letters have the power to persuade.”73  
G. Proponents of the Strict Interpretation of the FDCA 
Recent articles have suggested that millions of dollars of hGH are 
being prescribed illegally.74 One purpose of these articles was to 
address legal issues surrounding the prescription of hGH by doctors 
to adult patients who they have diagnosed as growth hormone 
deficient.75 It was stated in the JAMA article that “off-label” uses of 
hGH are illegal.76 In making this assertion, the authors cite only the 
FDCA itself and an obscure warning letter written by the FDA in 
2004.77 
Jim Edwards, in an article published in Brandweek, claimed that 
the 1990 law “explicitly bans anyone from promoting or selling 
growth hormone for off-label uses.”78 In the same article, Mr. 
Edwards asserts that the 1990 law is “so confusing that even 
seasoned drug marketers are in the dark about what it actually allows 
and prohibits.”79 
Accordingly, it is possible—and troubling to these authors—that 
someone who wants hGH, but does not want to purchase from a 
“dubious seller” on the internet, can try to get his doctor to prescribe 
it.80 It has been suggested that some of these doctors are measuring 
 
administrator of the United States Department of Labor’s Wage and Hour Division interpreting 
the Fair Labor Standards Act (FLSA). Id. at 580.  
 73. Id. at 587. The Court found the administrator’s opinion letter unpersuasive.  
 74. See Perls, supra note 1, at 2088; Edwards, supra note 4. 
 75. Perls, supra note 1, at 2086.  
 76. Id. at 2089. “[C]urrent law explicitly prohibits the distribution of GH except for 
clearly and narrowly defined indications. Distribution for other uses, or off-label use, such as 
for anti-aging, age-related conditions and enhancing athletic performance are illegal.” Id. 
 77. Id. at 2086. See also FDA Warning letter Chappell MA. to Tony Stires, Global 
Internet Alliance (Feb. 18, 2004), available at: http://www.fda.gov/foi/warning_letters/g4543d. 
htm.  
 78. Edwards, supra note 4.  
 79. Id. 
 80. Id. 
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IGF-1 levels instead of applying the two “on-label” diagnostic 
criteria.81  
When the IGF-1 levels are lower than those in young adults, 
doctors are mistakenly diagnosing growth hormone deficiency in 
adults.82 It is estimated that 50,000 adults in the United States are 
growth hormone deficient, many of whom are not treated with 
hGH.83 Further, only 1 out of 10,000 patients meet the on-label 
diagnostic criteria.84 This number compared with the over 200,000 
prescriptions written each year suggests that many doctors are using 
less precise means, perhaps testing IGF-1 levels, to diagnose adult 
growth hormone deficiency.85 A prescription based on this type of 
diagnosis would be off-label. 
In both articles, Dr. Perls supports two specific diagnostic criteria 
that, in his opinion, must be met before hGH is legally prescribed to 
treat growth hormone deficiency in adults.86 These two criteria are 
 
 81. Perls, supra note 1, at 2088. IGF-1 levels are a proxy for growth hormone levels. See 
also Angela Gentili and Robert A Adler, Growth Hormone Replacement in Older Men, 
available at http://www.emedicine.com/med/topic3178.htm (last updated July 15, 2005). 
The decrease in lean body mass and increase in adipose tissue that occurs with aging 
has been suggested to be partly due to the age-associated decrease in growth hormone 
(GH) and insulinlike growth factor-1 (IGF-1), also known as somatomedin C, which is 
produced by the liver and other tissues in response to GH. This decline in the secretory 
activity of the GH–IGF-1 axis has been termed somatopause or hyposomatotropism of 
aging. . . . 
GH is released from the anterior pituitary gland in a pulsatile manner. Two 
hypothalamic hormones control GH secretion: Growth hormone-releasing hormone 
(GHRH) stimulates GH secretion, and somatostatin inhibits it. The majority of GH 
secretion occurs at night during slow-wave sleep, when somatostatin release is 
diminished. . . . 
GH stimulates production of IGF-1 in the liver and other tissues. . . . Both GH and 
IGF-1 have important metabolic actions in several tissues. . . . 
A single measurement of plasma GH levels is difficult to interpret because of the 
pulsatile secretion of GH. Levels of IGF-1 vary but little during the day; therefore, 
assays of IGF-1 have been used as a better indicator of the status of the GH–IGF-1 
axis.  
Id. 
 82. Perls, supra note 1, at 2088.  
 83. Id. 
 84. Id. 
 85. See Perls, supra note 1.  
 86. Id.  
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included on many of the FDA approved labels which accompany the 
drug.87 Prescriptions of hGH based on meeting these two criteria are 
therefore on-label. There is a unanimous consensus that an on-label 
prescription of hGH is legal. 
Dr. Perls uses a letter written by a regulatory officer at the 
Department of Health and Human Services to a senior officer at 
Genentech, Inc. as sole support of his contention that these two 
prescription steps are in fact mandated by law.88 The purpose of the 
letter was to request that Genentech cease its dissemination of 
promotional materials for Nutropin (a growth hormone) without 
necessary risk information.89 The letter contained a list of the 
approved uses of hGH, and correctly specified the only “approved” 
use of hGH in adults.90 The letter makes no mention of off-label 
prescriptions.91 
 
These two criteria are: (1) biochemical diagnosis by means of a subnormal response to 
the standard growth hormone stimulation test (peak GF, < 5.0 ng/L), and (2) patient 
must be growth hormone deficient as a result of pituitary disease, hypothalamic 
disease, surgery, radiation therapy, or trauma or patients who were GH deficient 
during childhood.  
Id.; see also infra note 87. 
 87. See Perls, supra note 1. See also Tran, infra note 88. The label accompanying 
Nutropin products was attached with the letter. Id. 
 88. Letter from Debi Tran, Regulatory Review Officer, Division of Drug Marketing, 
Advertising, and Communications, Department of Health and Human Services to Robert L. 
Garnick, Ph.D., Senior Vice President, Regulatory Affairs, Quality & Corporate Compliance 
(Aug. 25, 2003) (on file with author). This letter objected to Genentech, Inc.’s dissemination of 
promotional materials related to certain hGH products. Id. The objection was that the company 
failed to provide risk information in its advertising materials. Id. The letter also indicated that 
approved hGH products (specifically Nutropin and Nutropin AQ) are only approved for use in 
adults who meet the two “on-label” diagnostic criteria. Id.  
 89. Id.  
Promotional materials are false or misleading if they fail to reveal facts material in 
light of representations made or with respect to consequences that may result from the 
use of the drug as recommended or suggested in the materials….The promotional 
panels are misleading because they present the indications and uses for the various 
formulations for Nutropin but entirely omit important risk information that is critical to 
the appropriate use of Nutropin.  
Id. 
 90. Id.  
Nutropin and Nutropin AQ are approved for the following indications” long-term 
treatment in pediatric patients with growth failure due to lack of adequate endogenous 
growth hormone (GH) secretion; treatment of growth failure in pediatric patients 
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Most FDA-approved drugs may be prescribed “off-label,” 
however, the FDA inteprets the FDCA to mandate all prescribing of 
hGH to be “on-label” (i.e., for an “authorized use”).92 The FDA’s 
strict interpretation of the statute limits hGH prescriptions to 
legitimate adult growth hormone deficiency when both on-label 
criteria are met. Prescribing hGH for any other reason, including 
diseases and medical research, would be prohibited. Even the 
Brandweek article characterizes this position as “an unusually strict 
view of the 1990 statute.”93 
H. Response from the Anti-Aging Community 
Rick Collins, in a lecture to the 13th Annual International 
Congress on Anti-Aging Medicine, stated that the interpretation of 
 
associated with chronic renal insufficiency up to the time of renal transplantation; and 
long-term treatment of short stature in pediatric patients with Turner syndrome. . . . 
Nutropin and Nutropin AQ are also approved for the replacement of endogenous GH 
in adult patients with GH deficiency who meet two criteria: 
(1) biochemical diagnosis of adult GH deficiency by means of a subnormal response 
to a standard growth hormone stimulation test (peak GH≤µ/L); and, 
(2) adult-onset patients who have adult GH deficiency either alone or with multiple 
hormone deficiencies (hypopituitarism) as a result of pituitary disease, hypothamic 
disease, surgery, radiation therapy, or trauma or childhood-onset patients who were 
GH deficient during childhood, confirmed as an adult before replacement therapy with 
Nutropin is started. Id. 
Nutropin Depot is approved for the following indication: the long-term treatment of 
growth failure in pediatric patients due to a lack of adequate endogenous GH secretion.  
Id. 
 91. Id. 
 92. Id. See also Collins, supra note 5. 
 93. Edwards, supra note 4.  
Confusion had grown in the industry as to what, exactly, the FDA now permitted. 
Marketers and doctors knew the drug was approved for adults-enough “of a green light 
for many in the industry. And so the 1990 law became a distant memory, even though 
it remains very much in effect.”  
Id. The FDA takes an unusually strict view of the 1990 statute. (The) FDA believes that a 
physician who prescribes, dispenses, and/or administers hGH for an unauthorized use violates 
federal law. Id. Richard Collier, former counsel to the pharmaceutical company Pharmecia 
doubts the FDA’s position is correct. Id. “It may be ill-advised or inappropriate to market off-
label but it is permissible for a physician to prescribe off-label.” Id. 
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the restrictions on hGH prescriptions is open to debate.94 Collins’ 
presentation, as cautionary as it was explanatory, cited the potential 
criminal enforcement ramifications of FDA’s strict interpretation of 
the FDCA. However, he suggested that the FDA’s strict 
interpretation of the FDCA is not what Congress intended.95 He 
conceded the problematic wording of the statute, stating that “(t)he 
law on hGH does (curiously) place greater limitations on hGH 
prescribing than on controlled substances, including anabolic 
steroids, which may be prescribed for any legitimate medical 
purpose.”96 But Collins notes that nothing in the legislative history 
suggests such a strict interpretation, citing Congress’ intent to curb 
hGH use as a performance enhancer in athletes but not as off-label 
prescriptions.97  
The U.S. Attorney’s online Civil Resource Manual states that the 
law “allows physicians to distribute human growth hormone in 
connection with either (1) “treatment of a disease” or (2) “other 
recognized medical condition” which has been authorized by the 
Secretary of Human Services.”98 Collins poses the question: “does 
the division as stated suggest that if the use is to treat a disease, as 
opposed to treating an ‘other . . . condition,’ the use need not be 
authorized by the FDA?.”99  
This interpretation of the statute treats the word “or” as 
disjunctive. The U.S. Attorney’s manual appears to read the statute 
the same way. Applying the disjunctive interpretation, hGH could be 
legally prescribed to an adult patient where there is “either, (1) some 
component of “disease” being legitimately treated (e.g., symptoms, 
evidence of biochemical deficiency, etc.) or (2) some other 
“recognized medical condition” and an FDA-approved use.”100  
 
 94. Collins, supra note 5.  
 95. Id. “[The] FDA’s extreme interpretation of the law’s restrictions seems to make no 
sense.” Id. 
 96. Id. 
 97. Id. “The objective was not to target anti-aging medicine (which had not yet come into 
existence) or specifically to restrict medical prescribing for disease, but to address the abuse of 
hGH by athletes to cheat in sports.” Id. 
 98. U.S. DEP’T OF JUSTICE, CIVIL RESOURCE MANUAL 19, HUMAN GROWTH HORMONE/ 
STEROIDS STATUTORY OVERVIEW (1998); see also Collins, supra note 5.  
 99. Id. 
 100. Id. 
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Collins argued that there are considerable benefits to this “correct” 
disjunctive construction of the FDCA.101 Specifically, the disjunctive 
reading of the FDCA “lets physicians, not bureaucrats, determine 
what’s best for patients with a disease.”102  
I. Just How Beneficial or Dangerous Might hGH Be to Adults? 
The extent of the potential costs and benefits from the use of hGH 
are not yet fully known. However, studies have shown both potential 
positive and negative effects of hGH. While the most commonly 
known effect of hGH in adults is muscle growth, it is possible that it 
has many more beneficial effects.  
Aging adults experience a variety of ailments that hGH could 
treat.103 For example, hGH has been shown to counteract the 
weakening of an adult’s immune system to some extent.104 Second, it 
has been shown that hGH can be effective in fighting skin cancer.105 
Third, hGH can improve declining brain function in aging adults.106 
 
 101. Id.  
 102. Id. Collins adds that at this reading doctors are able to apply the latest research data 
when appropriate. 
 103. Elmer M. Cranton, M.D. & William Fryer, hGH: The Body of Evidence (adapted from 
the book ELMER M. CRANTON, M.D. & WILLIAM FRYER, RESETTING THE CLOCK: 5 ANTI-
AGING HORMONES THAT ARE REVOLUTIONIZING THE QUALITY AND LENGTH OF LIFE (M. & 
Evans Co. 1996)), available at http://www.drcranton.com/hrt/hGH_Body of_Evidence.pdf. 
 104. Id. 
 105. Id. at 2.  
We already have evidence that growth hormone will indeed stimulate one kind of 
immunity in people. A study was conducted at the University of New Mexico School 
of Medicine on older women with low levels of human growth hormone.4 The 
researchers were intrigued by the correlation of two facts. First, that in both animals 
and humans a deficiency in growth hormone is associated with an impairment in 
natural killer (NK) cell activity. Second, that a decrease in NK activity occurs naturally 
with aging. . . . 
Recent research indicates that NK cells are designed to sense any cell that is dividing 
at an abnormally rapid rate—which is the exact characteristic of a cancer. NK cells go 
directly to such a site of abnormality; attach themselves to the suspect cell; and, acting 
as judge, jury, and executioner all in one, give it such a walloping dose of chemical 
toxicity that the offending malignant cell promptly croaks. Immunologists now believe 
that without these superb and necessary assassins, we would very quickly become 
statistics on the national cancer charts. Which is exactly what happens to a large 
percentage of AIDS patients as their natural killer cell counts go down.  
Id. 
 106. Id. at 6–7.  
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Fourth, hGH could be beneficial in treating patients with injuries to 
the central nervous system.107 Last, hGH has been shown in recent 
studies to be effective in combating obesity.108 While it is 
unnecessary here to examine all of the possible scientific data 
supporting beneficial uses of hGH, it is clear that there are many 
possibilities for the beneficial use of hGH in treating adults.  
Members of the Senate and House, encouraged by hGH’s safety 
record, have also supported loosening restrictions on hGH.109 On 
February 10, 2006, Senator Orrin Hatch and Congressman Henry 
Waxman sent a letter to the FDA arguing there “is simply no excuse 
—scientific, legal, or otherwise—for FDA to continue to delay the 
release of [guidance documents on the approval requirements for 
generic hGH versions],” adding that hGH is one of the biologic 
products with “relatively simple structures with a long history of safe 
use by millions of people. . . .”110 
There have also been indications that hGH could potentially harm 
adults. One study has shown a possible increase in the risk of prostate 
cancer when hGH is used in elderly patients.111 Another study has 
shown a dramatic increase in the occurrence of diabetes, carpal 
 
An important discovery of recent years is that growth hormone and its byproduct IGF-
1(somatomedin-C) can also act as nerve growth factors. If they too support the 
functioning of the central nervous system, then growth hormone’s decline may be in 
part responsible for the mental decline that many people experience with age. 
Certainly, as you’re about to see, replacement of hGH can have startling effects on 
people with many forms of neurological disorder-not just mental but physical as well.  
Id. 
 107. Id. at 7. Edward Chein, M.D. . . . has said with reference to growth hormone that “We 
have a therapy that can repair systems. Damage to the neurologic system resulting from age or 
injury can be repaired.” Id. Chaovanee Aroonsakul, M.D., of the Alzheimer’s and Parkinson’s 
Disease Diagnostic and Treatment Center in Naperville, Illinois, has discussed her own 
successes using growth hormone. Id. She has been able to demonstrate the regeneration of 
nerve cells, restored hormonal balance, and improved functional capacity in patients with 
Alzheimer’s disease, senile dementia, Parkinson’s disease, and stroke. Id. Dr. Aroonsakul 
writes that “Further experience with these methods has demonstrated their usefulness for a 
variety of age-related conditions including osteoporosis, osteoarthritis, sexual dysfunction, lack 
of stamina, and mental and physical slowing.” Id. 
 108. Akihiro Ikeda et al., Obesity and Insulin Resistance in Human Growth Hormone 
Transgenic Rats 139 ENDOCRINOLOGY 7, 3057–63 (1998). 
 109. Collins, supra note 5. 
 110. Id. 
 111. Vance, supra note 13, at 779. 
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tunnel syndrome, edema and arthralgias in patients treated with 
hGH.112 Another potential risk is that long-term treatment could 
significantly increase a patient’s risk of developing breast cancer.113 
Further, there have also been indications from tests performed on 
laboratory rodents that hGH might actually reduce life expectancy.114 
Some say the physical benefits of hGH may be overvalued. While 
hGH has been shown to change body composition, it has not been 
shown to improve function, strength or metabolism in aging adults. 
115 Further, one study suggests that the positive effects of hGH might 
be short-lived.116 
Skeptics worry that inappropriate prescription of hGH could cause 
an inefficient allocation of health care resources.117 Growth hormone 
replacement can cost between $7,500 and $10,000 annually.118 It is 
estimated that one third of the prescriptions of hGH in the United 
States are for off-label uses which are not approved by the FDA.119 
This leads to concerns that inappropriate prescriptions could end up 
being reimbursed, while the patients most in need will have a harder 
time being reimbursed because of increased “off-label” 
prescriptions.120 There is also a possible negative impact on third 
party payers, effectively having them pay the costs for arguably 
illegal prescriptions.121 
II. THE EFFECT OF FEDERAL REGULATION ON PHYSICIANS’ ABILITY 
TO PRESCRIBE HGH TO ADULTS OFF-LABEL 
On its face, the FDCA does not forbid the off-label prescription of 
hGH to adults. As a result, we face a dangerous situation where 
 
 112. Id. (citing MR Blackman et al., Growth Hormone and Sex Steroid Administration in 
Healthy Aged Women and Men: A Randomized Controlled Trial, 288 JAMA, 2282–92 (2002)).  
 113. Perls, supra note 1, at 2086. 
 114. Edwards, supra note 4. 
 115. Vance, supra note 13. 
 116. Perls, supra note 1, at 2086 (citing J Verhelst et al., Two Years of Replacement 
Therapy in Adults with Growth Hormone Deficiency, 47 CLINICAL ENDOCRINOLOGY (Ox) 485–
94 (1997)). 
 117. Vance, supra note 13, at 780. 
 118. Id. This number was calculated for a patient with GHd. 
 119. Id. 
 120. Id. 
 121. Id. 
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doctors are unsure whether prescribing hGH, a potentially effective 
course of treatment for off-label diseases, is illegal. A closer look at 
the statutory construction, Congressional intent, and policy 
considerations is necessary to determine whether doctors can legally 
prescribe hGH off-label. 
A. Legislative History Indicates No Congressional Intent to Limit 
Physicians’ Ability to Prescribe hGH Off-Label 
In 1990, Congress passed the Anabolic Steroid Control Act which 
made anabolic steroids a schedule III controlled substance.122 The Act 
also amended the FDCA to restrict illegal distribution of hGH.123 The 
legislative history makes clear that the 1990 Act was intended to 
curtail the use of anabolic steroids and hGH as athletic performance 
enhancers.124 Nowhere in the history is there any indication that 
Congress considered universally outlawing the off-label prescription 
of hGH.125 
The Anabolic Steroid Control Act of 1990 attempted to curb the 
growing problem of steroid abuse in America.126 Congress noted that 
“as many as 1 million Americans or more have used or are currently 
using steroids for non-medical purposes, primarily to increase athletic 
performance and improve physical appearance.”127 Before the 
passage of the  Act, the Senate Committee on the Judiciary held two 
full days of hearings which “focus[ed] on the problem of steroid 
abuse in amateur and professional sports.128 These hearings saw a 
parade of coaches, athletes, administrators, and doctors who all 
 
 122.  Pub. L. No. 101-647, Sec. 1902, 104 Stat. 4851 (1990), amending 21 U.S.C. § 812(c) 
(1981) to include anabolic steroids.  See also 21 U.S.C. § 802(41)(A). 
 123. 21 U.S.C. § 333 (e). 
 124. S. REP. NO. 101-433, at 1; see also, e.g., Steroids in Amateur and Professional 
Sports—The Medical and Social Costs of Steroid Abuse: Hearings Before the Senate Comm. on 
the Judiciary, 101st Cong. 1st Sess. 736, April 3 and May 9, 1989; Abuse of Steroids in 
Amateur and Professional Athletics: Hearings Before the Subcomm. on Crime of the House 
Comm. on the Judiciary, 101st Cong., 2d Sess. 92, March 22, 1990; Hearings on H.R. 4658 
Before the Subcomm. on Crime of the House Comm. on the Judiciary, 101st Cong., 2d Sess. 90, 
May 17, 1990.    
 125. See generally S. 1829, S. REP. NO. 101-433. 
 126. Id. 
 127. Id. 
 128. Id. 
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addressed the problem of steroid use by athletes.129 This extensive 
testimony on non-medical performance enhancement, coupled with 
the absence of testimony concerning medical uses, is the most 
obvious indication that this legislation was not intended to regulate 
medical prescriptions of hGH in adults. 
A second, and equally compelling indicator of congressional 
intent, is the illogical outcome that would result from a strict reading 
of the FDCA. Congress explicitly intended to place stronger 
restrictions on anabolic steroids in the Control Act.130 It accomplished 
this by making anabolic steroids a controlled substance under the 
Controlled Substances Act. 131 Simultaneously, Congress inserted 
hGH into the less restrictive FDCA, the same regulatory 
classification anabolic steroids had been in.132 This distinction made 
between hGH and anabolic steroids clearly and unambiguously 
shows congressional intent to regulate anabolic steroids on a stricter 
level than hGH.  
In contrast, proponents of a strict interpretation of the FDCA 
argue that hGH should be regulated at a higher level than anabolic 
steroids. Specifically advocating a ban on off-label prescriptions of 
hGH, regulation of hGH prescriptions would exceed similar 
regulations of anabolic steroids133 because anabolic steroids, and all 
other FDA approved schedule III drugs, can be prescribed off-
label.134 
Further, there was significant attention paid to the separation of 
hGH and anabolic steroids in the new legislation. The testimony of 
Dr. Underwood before the House Subcommittee on Crime paid 
particular attention to the vast differences (both in chemical makeup 
and risks) between hGH and anabolic steroids.135 Dr. Underwood 
 
 129. Id. 
 130. 21 U.S.C. § 812. 
 131. Id. 
 132. 21 U.S.C. § 333(e). 
 133. Id.; see also 21 U.S.C § 812(c ), and Collins, supra note 5.  
 134. Collins, supra note 5. 
 135. Hearing on the Abuse of Steroids in Amateur and Professional Athletics, supra note 
43. 
Washington University Open Scholarship
p 191 Cronin book pages  6/9/2009 9:00:00 AM 
 
 
 
 
 
 
 
 
 
214 Journal of Law & Policy [Vol. 27:191 
 
 
advocated that hGH not be “tarred by the same brush used for 
anabolic steroids.”136  
Congress seems to have agreed with Dr. Underwood as evidenced 
in the language of the committee report noting that hGH “is 
chemically distinct from steroids.”137 Secondly, as a result of these 
acknowledged distinctions, Congress declined to go as far as 
scheduling hGH as a controlled substance, and instead placed it into 
the less restrictive FDCA.138 And third, considering the placement of 
the hGH provision at the end of the statute, with no guidance as to 
what Congress intended, it must be assumed that heavy reliance was 
placed on Dr. Underwood’s testimony.139 As such, hGH was intended 
to be less regulated than anabolic steroids, especially in relation to its 
medical uses. 
B. The Proper Level of Administrative Deference Leaves the FDA’s 
Interpretation of the FDCA Unpersuasive 
The authors of the “Bad Medicine” article failed to cite any 
compelling legal authority for their strict interpretation of the FDCA. 
This is further proof that their interpretation is inaccurate.  
The authors site an obscure letter written from an officer at the 
FDA to a drug company that distributes hGH, which interprets the 
word “or” in the FDCA provision to be read conjunctively.140 The 
Supreme Court has held that opinion letters written by federal 
agencies are valuable only in their ability to persuade, and are not 
legally binding.141  
To the extent that the FDA’s interpretation is persuasive, it is 
counteracted by the Justice Department’s interpretation of the FDCA 
in its civil service manual, which reads “or” in the provision of the 
 
 136. Id. 
 137. S. 1829, S. REP. NO. 101-433 at 2. 
 138. 21 U.S.C. § 333(e). 
 139. Id.  
 140. Perls, supra note 1. Reading “or” conjunctively results in the phrase “authorized by 
the Secretary of Health and Human Services” applying to both “other recognized medical 
condition” and “treatment of a disease.” Id. 
 141. Christensen, 529 U.S. at 587. 
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FDCA disjunctively.142 Under Christensen, such a manual is granted 
the same level of deference as an opinion letter from the FDA.143 
C. Applying the Supreme Court’s Decision in Gonzalez v. Oregon to 
the Interpretation of the Food, Drug and Cosmetic Act 
The FDA, like the Attorney General in Gonzales v. Oregon, is 
attempting to reach beyond its power by applying a statute in a way it 
was not intended.144 Nothing in the FDCA restricts a doctor from 
prescribing hGH for medical purposes.145 Like in Gonzales v. 
Oregon, where the statute was intended to curb drug abuse,146 the 
FDCA was intended to curb the use of hGH as a performance 
enhancer.147 This is a far cry from the aging adults whom doctors 
have diagnosed as growth hormone deficient, or some other 
recognized medical condition.  
Further, Congress explicitly authorized the Drug Enforcement 
Agency (DEA) to enforce the FDCA.148 The DEA is an arm of the 
Department of Justice, not the FDA.149 Because Congress did not 
delegate authority to the FDA, the FDA is not entitled to “substantial 
deference.”150 Instead, like the Attorney General’s interpretation in 
Gonzales v. Oregon, it is entitled to respect only to the extent that it 
“has it has the power to persuade.”151 And like the Attorney General’s 
interpretation of the CSA in Gonzales, the FDA’s interpretation of 
 
 142. Collins, supra note 5. Reading “or” disjunctively results in the phrase “approved by 
the Secretary of Health and Human Services” applying only to “other recognized medical 
conditions(s)” leaving doctors free to prescribe hGH off-label to treat disease where that 
treatment was not approved by the Secretary of Health and Human Services. Id. 
 143. Christensen 529 U.S. at 587. “Interpretations such as those in opinion letters—like 
interpretations contained in policy statements, agency manuals, and enforcement guidelines, all 
of which lack the force of law—do not warrant Chevron-style deference.” Id. See also 
Skidmore, 323 U.S. at 140. 
 144. See generally Gonzales, 546 U.S. at 247. 
 145. See generally 21 U.S.C. § 333. 
 146. Gonzales, 546 U.S. at 246. 
 147. S. 1829, S. REP. NO. 101-433 at 1; see also Hearing on the Abuse of Steroids in 
Amateur and Professional Athletics supra note 44.  
 148. 21 U.S.C. § 333. 
 149. Exec. Order No. 11, 727, 38 Fed. Reg. 18,357 (July 6, 1973); see also Department of 
Justice Organization Chart (2006), available at http://www.usdoj.gov/ dojorg.htm.  
 150. 21 U.S.C. § 333; see also Chevron U.S.A., 467 U.S. at 845. 
 151. Gonzales v. Oregon, 546 U.S. at 908; see also Skidmore, 323 U.S. at 134, 140. 
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the FDCA is unpersuasive.152 For these reasons, the Supreme Court’s 
decision in Gonzales v. Oregon strongly supports the conclusion that 
hGH may be prescribed off-label. 
D. Established History of Off-Label Prescriptions Should Apply to 
hGH 
Scientific literature indicates that hGH has enormous potential to 
treat a broad spectrum of diseases beyond GHd. Further, Dr. 
Underwood’s testimony makes clear that hGH is not as dangerous as 
controlled performance enhancers such as anabolic steroids.153 While 
it is important that the FDCA be enforced to curb performance 
enhancers, including hGH, the statute should not be interpreted so 
strictly as to restrict doctors in treating disease. 
First, as is the case with so many other drugs, it may not be cost 
effective for drug companies to seek approval for other uses for 
hGH.154 If applied strictly, the FDCA could prevent countless 
treatments from being developed. It is in the public interest to prevent 
undue bureaucratic obstruction to innovation. 
Second, a strict application of the FDCA would remove some 
treatment decisions from the doctor-patient relationship and place 
them in the hands of bureaucrats.155 A potentially effective treatment 
supported by research should be available to patients so long as the 
drug has been approved by the FDA for some on-label use. 
CONCLUSION 
Doctors who prescribe hGH off-label for legitimate medical 
purposes should not face criminal liability for doing so. 
Unfortunately, opponents of hGH have taken advantage of public 
concern over performance enhancing drugs to advance their position 
to hinder off-label uses of hGH.156 Those that espouse a strict 
 
 152. Gonzales, 546 U.S. at 909. 
 153.  Hearing on the Abuse of Steroids in Amateur and Professional Athletics, supra note 
44. 
 154. Stoffelmayr, supra note 20, at 277. 
 155. Collins, supra note 5. 
 156. Id. “We have an atmosphere in which positive research findings receive scant 
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interpretation of the FDCA provision, including the FDA, base their 
arguments on legal analysis which is, at best, unsound.  
It is certainly foreseeable that doctors unfamiliar with statutory 
interpretation will become concerned by some of their colleagues’ 
articles and by the FDA’s position. It is important that these doctors 
not change their courses of treatment to avoid criminal liability under 
the FDCA. 
It is more important, however, that Congress speak with a clear 
voice on hGH regulation. The FDCA’s provision regulating hGH is 
confusing. Congress should pass new legislation which clearly guides 
doctors. Such legislation must take into consideration public policy 
implications that come with heavy restrictions on hGH. hGH has the 
potential to greatly help patients with certain conditions and there is 
evidence of its potential to help many more. There is also evidence 
cutting in the other direction. What is clear is that any new legislation 
must leave room for innovation so that physicians can put hGH to its 
most beneficial use. 
 
attention, but harsh criticism and negative attacks receive broad dissemination in both the 
scientific and law press.” Id.  
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